|
|
||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Thu., Apr. 25, 1:21 PM
|
|||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #2 of 25 |
Slide #2. Centessa Pharmaceuticals plc — Secondary Offering
Company:
Centessa Pharmaceuticals plc (NASDAQ:CNTA)
Date announced:
4/23/2024
Shares Offered:
10,810,810
Date of Pricing:
4/23/2024
Price Per Share:
$9.25
Secondary Offering Details:
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 4/23- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares ("ADSs"), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about April 26, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,621,621 ADSs at the public offering price, less underwriting discounts and commissions.
Centessa Pharmaceuticals is a pharmaceutical company that develops and delivers life-altering and life-enhancing medicines to patients. Co.'s product pipeline includes: Lixivaptan, a vasopressin V2 receptor small molecule inhibitor; SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin for the treatment of alpha-1-antitrypsin deficiency.
Open the CNTA Page at The Online Investor »
|
|||||||||||||||
Open the CNTA Page at The Online Investor (in a new window) »
 Free CNTA Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.43 out of 4) 53rd percentile
(ranked higher than approx. 53% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.